共查询到20条相似文献,搜索用时 15 毫秒
1.
Hyperglycemia is frequent during critical illness and is perceived by the clinician as part of the systemic metabolic response to stress. Of all patients with "stress hyperglycemia" only one third are known to have diabetes mellitus. Previous studies reported that patients presenting hyperglycemia during acute illness have an increased risk for nosocomial infections. Morbidity and mortality also increases in patients with myocardial infarction or stroke who develop hyperglycemia. Contemporary medical practice states that hyperglycemia under these conditions should only be treated with insulin if blood glucose levels are > 200 mg/dl. A recent trial showed that intensive insulin treatment of critically ill patients in the intensive care unit with the goal of maintaining blood glucose levels between 80 and 110 mg/dl significantly reduced morbidity and mortality without significant risk of hypoglycemia. These benefits of insulin treatment are not yet well understood, but some pathophysiological evidence suggests that hyperglycemia contributes to perpetuate the systemic proinflammatory response, and insulin--a natural endogenous hormone that has a major role in the intermediary metabolism--participates actively in the systemic anti-inflammatory response. As a result of these findings, we recommend that hyperglycemia during critical illness should be treated with insulin, in order to achieve blood glucose levels in a normal range, regardless of whether or not these patients have diabetes mellitus. 相似文献
2.
为了解糖尿病人胰岛素水平的高低对骨代谢影响和程度,检测其馒头餐前后胰岛素和血糖水平,用跟骨超声波传导速度(SOS)、振幅衰减(BUA)和骨硬度指数(STI)。结果显示糖尿病各组SOS、BUA及STI均低于对照组,其中以胰岛素分泌低下组最明显,分泌延迟组和分泌过高组比较无显差异。组间比较,胰岛素分泌低下组胰岛素水平最低,而相应时限血糖值最高。胰岛分泌过高组胰岛素水平最高,但相应血糖值高于对照组,并 相似文献
3.
Prashant Nasa Sandeep Chaudhary Pavan Kumar Shrivastava Aanchal Singh 《World journal of diabetes》2021,12(5):514-523
Euglycemic diabetic ketoacidosis(DKA) is an acute life-threatening metabolic emergency characterized by ketoacidosis and relatively lower blood glucose(less than 11 mmol/L). The absence of hyperglycemia is a conundrum for physicians in the emergency department and intensive care units; it may delay diagnosis and treatment causing worse outcomes. Euglycemic DKA is an uncommon diagnosis but can occur in patients with type 1 or type 2 diabetes mellitus. With the addition of sodium/glucose cotransporter-2 inhibitors in diabetes mellitus management, euglycemic DKA incidence has increased. The other causes of euglycemic DKA include pregnancy, fasting, bariatric surgery, gastroparesis, insulin pump failure, cocaine intoxication, chronic liver disease and glycogen storage disease. The pathophysiology of euglycemic DKA involves a relative or absolute carbohydrate deficit, milder degree of insulin deficiency or resistance and increased glucagon/insulin ratio. Euglycemic DKA is a diagnosis of exclusion and should be considered in the differential diagnosis of a sick patient with a history of diabetes mellitus despite lower blood glucose or absent urine ketones. The diagnostic workup includes arterial blood gas for metabolic acidosis, serum ketones and exclusion of other causes of high anion gap metabolic acidosis. Euglycemic DKA treatment is on the same principles as for DKA with correction of dehydration, electrolytes deficit and insulin replacement. The dextrosecontaining fluids should accompany intravenous insulin to correct metabolic acidosis, ketonemia and to avoid hypoglycemia. 相似文献
4.
糖尿病主要是以胰岛素分泌缺陷或胰岛素作用障碍导致的以高血糖为主的代谢性疾病。大量的临床研究及动物研究证实,糖尿病患者骨代谢易紊乱,多发骨质疏松等疾病。胰岛素分泌对骨代谢具有十分重要的作用。本文分别从高血糖环境、胰岛素及高血脂环境对糖尿病患者骨代谢的影响进行详细综述,探讨其影响骨代谢、造成骨质疏松的相关机制。此外,通过分析运动改善糖尿病患者骨代谢,为体育锻炼防治糖尿病患者骨质疏松等疾病提供基础理论参考。 相似文献
5.
Treatment of type 1 diabetes mellitus has always posed a challenge to balance hyperglycemia control with hypoglycemia episodes. The quest for newer therapies is continuing and this review attempts to outline the recent developments. The insulin molecule itself has got moulded into different analogues by minor changes in its structure to ensure well controlled delivery, stable half-lives and lesser side effects. Insulin delivery systems have also consistently undergone advances from subcutaneous injections to continuous infusion to trials of inhalational delivery. Continuous glucose monitoring systems are also becoming more accurate and user friendly. Smartphones have also made their entry into therapy of diabetes by integrating blood glucose levels and food intake with calculated adequate insulin required. Artificial pancreas has enabled to a certain extent to close the loop between blood glucose level and insulin delivery with devices armed with meal and exercise announcements, dual hormone delivery and pramlintide infusion. Islet, pancreas-kidney and stem cells transplants are also being attempted though complete success is still a far way off. Incorporating insulin gene and secretary apparatus is another ambitious leap to achieve insulin independence though the search for the ideal vector and target cell is still continuing. Finally to stand up to the statement, prevention is better than cure, immunological methods are being investigated to be used as vaccine to prevent the onset of diabetes mellitus. 相似文献
6.
We investigated the impact of blood glucose normalization on plasma levels of somatostatin-like immunoreactivity (SLI) in subjects with C-peptide-negative insulin-dependent diabetes mellitus (IDDM) and in totally pancreatectomized patients. Patients were studied during hyperglycemia and during normoglycemia, which was attained by Biostator-directed feedback insulin infusion. The experiments were performed in the fasted state and after a standardized breakfast. In IDDM (n = 6), basal levels of SLI were significantly higher than in nondiabetic subjects (n = 18). In IDDM, normalization of hyperglycemia was followed by a 40% decline in basal SLI (P less than .05). After the meal, SLI increased to the same absolute levels with or without feedback insulin treatment; however, the incremental response was 60% higher during feedback insulin treatment (P less than .05). Treatment also suppressed fasting and postprandial levels of glucagon, whereas gastric inhibitory polypeptide (GIP) levels were unaltered. In four pancreatectomized patients, normoglycemia tended to lower plasma levels of SLI by 50% (P less than .1). After breakfast, an SLI response was noted during normoglycemia, whereas no significant effect of the meal was seen during hyperglycemia. We conclude that in IDDM and in totally pancreatectomized patients, administration of insulin with subsequent normalization of blood glucose is accompanied by a decline in plasma levels of SLI in the fasted state, whereas the apparent response to a meal is enhanced. These effects on plasma levels of SLI probably reflect to a major extent release of somatostatin from the gastrointestinal tract. 相似文献
7.
Fujinaga A Terao Y Tanabe T Yamasiita K Ando Y Fukusaki M 《Masui. The Japanese journal of anesthesiology》2007,56(2):175-177
A 50-year-old male patient developed diabetic ketoacidosis with shock, acute renal failure treated with continuous hemodiafiltration (CHDF) and high serum CPK levels. Because of acute onset of ketoacidosis accompanied with an elevation of serum amylase, and negative findings of antibodies associated with autoimmune type 1 diabetes mellitus, he was diagnosed as a fulminant type 1 diabetes mellitus, which is a newly established subtype of type 1 diabetes mellitus. We managed to keep blood glucose concentrations within 150-200 mg x dl(-1) with continuous insulin intravenous infusion, and controlled circulation with dopamine. Since the blood glucose on admission was extremely high (1,870 mg x dl(-1)), the severe dehydration due to extreme hyperglycemia might have caused acute renal failure (ARF) and rhabdomyolysis. He was treated with CHDF for them. In a case of fulminant type 1 diabetes mellitus complicated with ARF early intensive support including CHDF for ARF must be considered in addition to intensive insulin therapy. 相似文献
8.
Askiel Bruno David Liebeskind Qing Hao Radoslav Raychev for the UCLA Stroke Investigators 《Current treatment options in neurology》2010,12(6):492-503
Acute brain ischemia is a dynamic process susceptible to multiple modulating factors, such as blood glucose level. During
acute ischemic brain injury, hyperglycemia exacerbates multiple deleterious derangements. Timely and sufficient correction
of hyperglycemia during acute brain ischemia may limit the brain injury and improve clinical outcomes. The clinical efficacy
of such intervention remains to be proven. Although results from animal and clinical observational studies suggest that hyperglycemia
during acute brain ischemia may exacerbate the brain injury, there is no evidence from randomized treatment trials that rapid
correction of the hyperglycemia improves outcomes. Given the excess effort, cost, and risk involved in rapid and safe correction
of hyperglycemia during acute stroke, less aggressive treatments with subcutaneous insulin seem appropriate at this time.
Subcutaneous insulin protocols can maintain blood glucose levels below 200 mg/dL a majority of the time in most patients,
especially if basal insulin is added. When available, an endocrinology consultant can optimize the acute treatment and help
the transition to long-term care. Given the multiple reports linking admission hyperglycemia with symptomatic hemorrhagic
conversion of ischemic stroke treated with thrombolytic drugs, it may be best to rapidly lower severe hyperglycemia in such
patients. For example, if the admission blood glucose is approximately 300 mg/dL and the patient is a candidate for thrombolytic
therapy, consider giving an intravenous bolus of regular insulin 8 units. Somewhat lower or higher insulin doses may be best
for lesser or greater hyperglycemia. Such a bolus will start lowering the blood glucose in about 5 min. A temporary continuous
intravenous insulin infusion may then be used in most patients to maintain the glucose closer to normal levels (eg, below
180 or 140 mg/dL). 相似文献
9.
Ya-Ling Chung Yi-Chou Hou I-Kuan Wang Kuo-Cheng Lu Tzung-Hai Yen 《World journal of diabetes》2021,12(11):1818-1831
Organophosphate is a commonly used pesticide in the agricultural sector. The main action of organophosphate focuses on acetylcholinesterase inhibition, and it therefore contributes to acute cholinergic crisis, intermediate syndrome and delayed neurotoxicity. From sporadic case series to epidemiologic studies, organophosphate has been linked to hyperglycemia and the occurrence of new-onset diabetes mellitus. Organophosphate-mediated direct damage to pancreatic beta cells, insulin resistance related to systemic inflammation and excessive hepatic gluconeogenesis and polymorphisms of the enzyme governing organophosphate elimination are all possible contributors to the development of new-onset diabetes mellitus. To date, a preventive strategy for organophosphate-mediated new-onset diabetes mellitus is still lacking. However, lowering reactive oxygen species levels may be a practical method to reduce the risk of developing hyperglycemia. 相似文献
10.
There are an estimated 14 million individuals in the United States with diabetes mellitus. These individuals suffer a very high incidence of podiatric complications. This article focuses on the pharmacologic agents used in the management of hyperglycemia in the patient with diabetes mellitus, including insulin and sulfonylureas. 相似文献
11.
Postprandial hyperglycemia is associated with platelet activation. We thus investigated if meal-induced platelet activation could be attenuated by meal insulin. A randomized, double-blind, cross-over study was performed to compare postprandial platelet activation after premeal injections of placebo or insulin aspart (0.1 and 0.2 units/kg) in 18 patients with type 2 diabetes mellitus (T2DM). Platelet activation was assessed by flow cytometry, without and with stimulation by the thromboxane analog U46619 or ADP. Measurements were before and after premeal blood glucose standardization (to 6-7 mmol/L by insulin infusion, if needed) and at 90 min after the meal. Premeal insulin reduced postprandial hyperglycemia by 2-3 mmol/L compared with placebo. Postmeal insulin levels were doubled with placebo and further elevated with insulin injections. The standardized meal enhanced U46619-induced platelet P-selectin expression by 23% after placebo; this response was more than doubled after premeal insulin. U46619-induced fibrinogen binding was unchanged after meal intake with placebo but was markedly enhanced (by ~50-60%) after premeal insulin. Postprandial platelet activation correlated positively to postprandial insulin levels and inversely to glucose levels. Premeal insulin infusion was also associated with platelet activation. Our results suggest that postprandial insulin rather than glucose accounts for postprandial platelet activation in T2DM patients. 相似文献
12.
Opinion statement Clinically recognized disorders of glucose metabolism include impaired fasting glucose, impaired glucose tolerance (both termed
prediabetes), and diabetes mellitus. Type 2 diabetes mellitus affects 6% to 13% of adults in the United States. Among patients
with recent stroke, 70% will have known diabetes, occult diabetes (detectable on an oral glucose tolerance test), or prediabetes.
Type 2 diabetes mellitus is associated with a two- to six-fold increased risk for first or recurrent ischemic stroke. The
mechanisms for the association are myriad and include the effects of hyperglycemia on vascular tissues and coagulation, and
aberrations in blood pressure regulation, lipid metabolism, endothelial function, vascular inflammation, lipid metabolism,
smooth muscle cell proliferation, and fibrinolysis. The most effective strategies to prevent stroke among people with diabetes
include blood pressure control, antiplatelet therapy, and statin therapy. Tight glycemic control is recommended to prevent
microvascular disease, but the effect on macrovascular disease, including stroke, has not been proven. Target blood pressure
should be less than 130/80. Antiplatelet therapy may be accomplished with 81 to 325 mg of aspirin daily or 75 mg of clopidogrel
daily. Statins should be given in dosages effective to reduce lowdensity lipoprotein cholesterol to less than 100 mg/dL. For
glycemic control, first line therapy for most patients is metformin, starting at 500 mg daily. With time, most patients will
need two or three oral medications from different classes and many eventually will require insulin therapy. Prevention of
diabetes may be best accomplished by identifying those at risk and modifying diet, weight, and exercise habits. Screening
for prediabetes and diabetes is appropriate for men and women older than 45 years and all individuals with vascular disease.
Insulin resistance and impaired insulin secretion is the major underlying defect in type 2 diabetes mellitus. It also affects
50% of nondiabetic subjects with a recent ischemic stroke. Emerging evidence has linked insulin resistance to the pathophysiologic
derangements in type 2 diabetes mellitus that accelerate atherosclerosis. Treatment of insulin resistance with weight loss,
exercise, or medication can correct these derangements, and represents a promising approach to stroke prevention. 相似文献
13.
There is considerable clinical evidence that hyperglycemia at the onset of acute ischemic stroke may negatively impact not
only acute morbidity but also brain recovery. Establishing hyperglycemia treatment protocols is challenging, given the variation
among patients and acute stroke care settings. Relatively few randomized trials have examined glycemic control protocols in
this population, and there is not yet any clear evidence that “correcting” hyperglycemia in patients with acute stroke leads
to better functional outcomes. Intensification of glucose regimens, using lower glucose targets, leads to more hypoglycemic
events, but the immediate and long-term impact of these events on the acutely ischemic brain is unknown. It is reasonable
to treat patients with acute ischemic stroke according to the American Diabetes Association inpatient glycemic control guidelines,
initiating therapy to achieve glucose targets of 140 to 180 mg/dL if fasting glucose is greater than 140 mg/dL or random glucose
is consistently higher than 180 mg/dL. Lower glucose targets (<140 mg/dL) may be appropriate for patients with well-controlled
diabetes and those with stress hyperglycemia who were not known to be diabetic before admission, but glucose levels less than
80 mg/dL should be avoided. Patients who present with extreme or persistent hyperglycemia, are critically ill, or who are
treated with thrombolytic therapy should be started on an established and standardized intravenous insulin protocol to improve
blood glucose control for at least the first 24 to 48 h of hospitalization. They should then be transitioned to a subcutaneous
insulin regimen that includes basal long-acting insulin along with correction rapid-acting insulin for glucose that is out
of range. Prandial (meal) insulin should be added for patients who are eating; this would preferably be a rapid-acting insulin
analogue that can be administered immediately before or after the meal. Caution and close glucose monitoring are necessary,
especially for patients prone to hypoglycemia, such as those with type 1 diabetes mellitus or hepatic or renal impairment,
or those on complicated feeding regimens. 相似文献
14.
M Press S Caprio W V Tamborlane R Bhushan M Thorner W Vale J Rivier R S Sherwin 《Diabetes》1992,41(1):17-21
In poorly controlled insulin-dependent diabetes mellitus (IDDM), hyperglycemia fails to inhibit the pituitary response to growth hormone-releasing factor (GRF). To evaluate whether this derangement is reversed by a simultaneous elevation of circulating insulin, 0.3 micrograms/kg i.v. GRF 1-40 was administered to nine poorly controlled IDDM subjects (HbA1 greater than 11.1%) with and without concomitant infusion of insulin. In the absence of insulin, the poorly controlled IDDM subjects demonstrated a growth hormone response to GRF similar to that of nondiabetic subjects, despite marked hyperglycemia (approximately 16.8 mM). When insulin was infused into these same patients (insulin clamp) to produce combined hyperinsulinemia (528 +/- 90 pM) and hyperglycemia (16.5 +/- 1.98 mM), the GRF-induced growth hormone rise was markedly exaggerated (65 +/- 11 vs. 20 +/- 4 micrograms/L without insulin infusion, P less than 0.001). This enhancement of GRF-stimulated growth hormone release by insulin was strikingly attenuated (22 +/- 7 micrograms/L) in five well-controlled diabetic subjects studied under conditions of similar hyperinsulinemia (486 +/- 84 pM) and hyperglycemia (16.41 +/- 0.95 mM). In contrast, in nondiabetic subjects, acute hyperinsulinemia reduced the growth hormone response to GRF. We conclude that the failure of hyperglycemia to block the pituitary response to GRF in poorly controlled diabetes is not attributable to the lack of a coincident increase in circulating insulin. The paradoxical stimulatory effect of insulin on GRF-induced growth hormone release may contribute to the high spontaneous growth hormone levels characteristically seen in poorly controlled insulin-treated patients, and its attenuation after intensive insulin therapy may contribute to the reversal of growth hormone hypersecretion in well-controlled diabetic patients. 相似文献
15.
Reach G 《Presse medicale (Paris, France : 1983)》2000,29(35):1939-1946
This paper presents an analysis of an aspect of non-observance in the treatment of type 1 diabetes mellitus, the absence of adaptation of insulin dosage in spite of hyperglycemia. The adaptation of insulin dosage by the patient is described as an intentional action, performed as a habit. The problem is analysed through the causal theory of action and the concept of akrasia. These considerations may be useful to understand other aspects of therapeutic non-observance. 相似文献
16.
Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice 总被引:3,自引:0,他引:3
C57BL/KsJ db/db mice develop hyperphagic obesity and nonketotic diabetes similar to non-insulin-dependent diabetes mellitus in humans. Initially the mice demonstrate an abundant beta-cell mass and hyperinsulinemia, which is followed by apparent beta-cell loss. As an index of insulin synthesis, this study assesses pancreatic proinsulin mRNA, measured by dot hybridization to cloned cDNA, during the development of diabetes in the mice. Changes in proinsulin mRNA from 5 to 13 wk of age are compared with serum insulin, pancreatic insulin content, and blood glucose. In control (+/db) mice, total proinsulin mRNA and pancreatic insulin content increased with age. Both changes were proportional to an increase in body weight. Obesity, hyperglycemia, and hyperinsulinemia were evident in diabetic (db/db) mice at 5 wk of age. Although pancreatic insulin content was comparable to that in the +/db controls at 5 wk, a fourfold relative elevation of proinsulin mRNA was observed. Despite an increase in body weight, proinsulin mRNA concentration and total proinsulin mRNA fell to levels similar to those of the control mice at 10 and 13 wk, associated with a loss of hyperinsulinemia, a mild decrease in pancreatic insulin content, and a marked increased in fasting blood glucose. A separate group of db/db mice was pair fed with the +/db controls from 4 to 13 wk. These diet-restricted diabetic mice were heavier than control mice and gained weight with age, but they weighed less than the unrestricted mice at all ages. Compared with the unrestricted db/db mice, a more modest fasting hyperglycemia was apparent, and a persistent hyperinsulinemia was observed.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
17.
Surapon Tangvarasittichai 《World journal of diabetes》2015,6(3):456-480
Oxidative stress is increased in metabolic syndrome and type 2 diabetes mellitus(T2DM) and this appears to underlie the development of cardiovascular disease,T2 DM and diabetic complications.Increased oxidative stress appears to be a deleterious factor leading toinsulin resistance,dyslipidemia,β-cell dysfunction,impaired glucose tolerance and ultimately leading to T2 DM.Chronic oxidative stress,hyperglycemia and dyslipidemia are particularly dangerous for β-cells from lowest levels of antioxidant,have high oxidative energy requirements,decrease the gene expression of key β-cell genes and induce cell death.If β-cell functioning is impaired,it results in an under production of insulin,impairs glucose stimulated insulin secretion,fasting hyperglycemia and eventually the development of T2 DM. 相似文献
18.
Impaired insulin biosynthetic capacity in a rat model for non-insulin-dependent diabetes. Studies with dexamethasone 总被引:1,自引:0,他引:1
These studies of a rat model for non-insulin-dependent diabetes mellitus (NIDDM) were performed to determine whether hyperglycemia occurs when capacity to synthesize insulin is exceeded. The neonatal streptozocin (STZ)-treated rat has acute hyperglycemia with marked destruction of pancreatic beta-cells, followed by gradual regeneration to 50-70% normal beta-cell number. At age 4 wk, fed serum glucose concentration is only mildly elevated relative to controls. With age, the rats become progressively hyperglycemic, and by 12 wk they have marked impairment of glucose-stimulated insulin release. In these studies, dexamethasone (0.125 mg/kg/day for 4 days) was administered to control and to STZ-treated animals to produce insulin resistance. The relationship between insulin biosynthesis and serum glucose concentrations was assessed. In control rats, response to dexamethasone was similar at both 4 and 12 wk. Serum glucose levels and pancreatic insulin concentration remained unchanged. Both insulin biosynthetic rates (as measured by 3H-leucine incorporation into proinsulin) and proinsulin mRNA levels increased twofold. STZ-treated rats at age 4 wk demonstrated mild hyperglycemia. Dexamethasone injection resulted in an increase in insulin biosynthesis and proinsulin mRNA in these animals, while serum glucose did not increase. STZ-treated rats at 12 wk showed more profound hyperglycemia (serum glucose 315 +/- 38 mg/dl versus control, 187 +/- 12 mg/dl). A marked rise in serum glucose (to 519 +/- 42 mg/dl) was observed after 4 days of dexamethasone injection. Pancreatic insulin content became severely depleted relative to saline-injected, STZ-treated animals, and there was no response of levels of proinsulin mRNA. 相似文献
19.
Diabetes mellitus is the fourth most common comorbid condition among hospitalized patients, and 30% of patients undergoing open-heart surgery have diabetes. The link between hyperglycemia and poor outcome has been well described, and large clinical trials have shown that aggressive control of blood glucose with an insulin infusion can improve these outcomes. The barriers to implementing an insulin infusion protocol are numerous, despite the fact that doing so is paramount to clinical success. Barriers include safety concerns, such as fear of hypoglycemia, insufficient nursing staff to patient ratios, lack of administrative and physician support, various system and procedural issues, and resistance to change. Key steps to overcome the barriers include building support with multidisciplinary champions, involving key staff, educating staff, and administrators of the clinical and economic benefits of improving glycemic control, setting realistic goals, selecting a validated insulin infusion protocol, and internally marketing the success of the protocol. 相似文献
20.
Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats 总被引:6,自引:0,他引:6
Nondiabetic rats were infused with glucose for 48 h to maintain moderate or marked hyperglycemia (mean blood glucose 13.2 +/- 0.7 or 22.8 +/- 0.3 mM, respectively). The two levels of hyperglycemia increased plasma insulin levels severalfold but decreased the insulin response to 27 mM glucose by 19 and 95%, respectively, versus saline infusion. Diazoxide (5 mg.kg-1.h-1), when continuously infused during the hyperglycemia protocols, completely inhibited the glucose-induced rise in plasma insulin levels. Diazoxide transformed beta-cell insensitivity to stimulation: glucose-induced insulin release was thus increased 318% after moderate hyperglycemia and 707% after marked hyperglycemia. These stimulatory effects of diazoxide were reversed by exogenous insulin infusion (8 or 2 U/24 h) in a dose-dependent manner. It is concluded that excessive beta-cell stimulation rather than glucotoxicity underlies hyperglycemia-induced beta-cell insensitivity. Effects of hyperinsulinemia can form part of the mechanisms whereby excessive stimulation affects beta-cell secretion. 相似文献